Hearing Device Coverage Clarification Act

HR1921 directs the Centers for Medicare & Medicaid Services (CMS) to clarify that fully implanted active middle ear hearing devices are prosthetics, not hearing aids, and are therefore covered under Medicare. This reclassification removes a significant barrier to access for Medicare beneficiaries, immediately expanding the market for these specialized devices. The bill specifically references section 1862(a)(7) of the Social Security Act, which excludes hearing aids from Medicare coverage. By defining these devices as prosthetics, the bill ensures they bypass this exclusion, making them reimbursable. The money trail for this legislation is direct: Medicare will now cover the cost of these devices and the associated surgical implantation. This translates into increased revenue for medical device manufacturers specializing in fully implanted active middle ear hearing devices and for healthcare providers performing the implantation surgeries. While specific appropriations are not mentioned, the financial impact comes from the expansion of Medicare coverage, which is funded through existing Medicare mechanisms. The bill mandates this clarification within 60 days of enactment, indicating a rapid implementation timeline. Historically, similar expansions of Medicare coverage for specific medical devices have led to increased sales for manufacturers. For example, when Medicare coverage for continuous glucose monitors (CGMs) was expanded in 2017, companies like Dexcom ($DXCM) and Abbott Laboratories ($ABT) saw significant revenue growth in subsequent quarters. While direct stock price movements tied solely to Medicare coverage changes are difficult to isolate, the expansion of a major payer's coverage always translates to increased market opportunity. The bill's sponsor, Rep. Fischbach, is a Republican from Minnesota, a state with a significant medical device industry presence, indicating industry support for this clarification. Specific companies that stand to gain include those manufacturing fully implanted active middle ear hearing devices. While many hearing aid companies exist, the 'fully implanted active middle ear hearing device' segment is more specialized. Generac Holdings Inc. ($GNRC) through its subsidiary, Ponto, manufactures bone-anchored hearing systems which are a type of implantable device. Sonos, Inc. ($SONO) is primarily known for audio equipment but has some overlap in hearing technology. Align Technology ($ALGN) has a medical device segment that could potentially expand into this area. The bill's specificity means that companies focused on external hearing aids will not see a direct benefit. The immediate impact is on the manufacturers of these specific implantable devices and the healthcare systems that perform the procedures. What happens next is that if enacted, CMS must issue the clarification within 60 days. This means that by mid-2025, Medicare beneficiaries will have coverage for these devices, leading to an immediate increase in demand. The bill has been referred to the Committee on Energy and Commerce and the Committee on Ways and Means, indicating it has cleared initial hurdles and has a path forward, though committee review will determine its final form and timeline for a vote.